Search research articles
Contact Us
Filters
Showing results (71-80 of 87) with videos related to
Page
of 9
Sort By:
Cancer Medicine
|
November 15, 2019
Every-other-day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the "Rete Ematologica Pugliese"
Nicola Di Renzo, Lorella Melillo, Fernando Porretto, et al.
European Heart Journal
|
September 6, 2006
Patterns of restenosis after drug-eluting stent implantation: Insights from a contemporary and comparative analysis of sirolimus- and paclitaxel-eluting stents
Simon J Corbett, John Cosgrave, Gloria Melzi, et al.
Annals of Surgery
|
July 22, 2006
The ILAILL study: iloprost as adjuvant to surgery for acute ischemia of lower limbs: a randomized, placebo-controlled, double-blind study by the italian society for vascular and endovascular surgery
Gaetano de Donato, Gualberto Gussoni, Gianmarco de Donato, et al.
The Lancet. Oncology
|
September 4, 2009
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study
Giancarlo Agnelli, Gualberto Gussoni, Carlo Bianchini, et al.
JAMA
|
May 5, 2005
Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents
Ioannis Iakovou, Thomas Schmidt, Erminio Bonizzoni, et al.
Circulation. Cardiovascular Interventions
|
May 6, 2010
Comparison of the long-term safety and efficacy of drug-eluting and bare-metal stent implantation in saphenous vein grafts
Azeem Latib, Luca Ferri, Alfonso Ielasi, et al.
BMC Infectious Diseases
|
November 10, 2016
Epidemiology and outcome of Clostridium difficile infections in patients hospitalized in Internal Medicine: findings from the nationwide FADOI-PRACTICE study
Giorgio Cioni, Pierluigi Viale, Stefania Frasson, et al.
Circulation
|
August 1, 2007
Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment
Flavio Airoldi, Antonio Colombo, Nuccia Morici, et al.
BMC Cancer
|
March 20, 2020
Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study
Roberta Caputo, Marina Elena Cazzaniga, Andrea Sbrana, et al.
Bone Marrow Transplantation
|
April 30, 2020
Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin's lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study
Nicola Di Renzo, Maurizio Musso, Rosanna Scimè, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 87) with videos related to
Sort By:
Page
of 9
Cancer Medicine
|
November 15, 2019
Every-other-day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the "Rete Ematologica Pugliese"
Nicola Di Renzo, Lorella Melillo, Fernando Porretto, et al.
European Heart Journal
|
September 6, 2006
Patterns of restenosis after drug-eluting stent implantation: Insights from a contemporary and comparative analysis of sirolimus- and paclitaxel-eluting stents
Simon J Corbett, John Cosgrave, Gloria Melzi, et al.
Annals of Surgery
|
July 22, 2006
The ILAILL study: iloprost as adjuvant to surgery for acute ischemia of lower limbs: a randomized, placebo-controlled, double-blind study by the italian society for vascular and endovascular surgery
Gaetano de Donato, Gualberto Gussoni, Gianmarco de Donato, et al.
The Lancet. Oncology
|
September 4, 2009
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study
Giancarlo Agnelli, Gualberto Gussoni, Carlo Bianchini, et al.
JAMA
|
May 5, 2005
Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents
Ioannis Iakovou, Thomas Schmidt, Erminio Bonizzoni, et al.
Circulation. Cardiovascular Interventions
|
May 6, 2010
Comparison of the long-term safety and efficacy of drug-eluting and bare-metal stent implantation in saphenous vein grafts
Azeem Latib, Luca Ferri, Alfonso Ielasi, et al.
BMC Infectious Diseases
|
November 10, 2016
Epidemiology and outcome of Clostridium difficile infections in patients hospitalized in Internal Medicine: findings from the nationwide FADOI-PRACTICE study
Giorgio Cioni, Pierluigi Viale, Stefania Frasson, et al.
Circulation
|
August 1, 2007
Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment
Flavio Airoldi, Antonio Colombo, Nuccia Morici, et al.
BMC Cancer
|
March 20, 2020
Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study
Roberta Caputo, Marina Elena Cazzaniga, Andrea Sbrana, et al.
Bone Marrow Transplantation
|
April 30, 2020
Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin's lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study
Nicola Di Renzo, Maurizio Musso, Rosanna Scimè, et al.
Page
of 9